A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors

Fable Zustovich; Giuseppe Cartei; Renato Ceravolo; Stefania Zovato; Alessandro Della Puppa; Davide Pastorelli; Martina Mattiazzi; Roberta Bertorelle; Marina Paola Gardiman

A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors

Fable Zustovich, Giuseppe Cartei, Renato Ceravolo, Stefania Zovato, Alessandro Della Puppa, Davide Pastorelli, Martina Mattiazzi, Roberta Bertorelle, Marina Paola Gardiman

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Background: There is pre-clinical evidence of synergism between cisplatin (P) and temozolomide (T) due to higher inhibition by T of O⁶-alkyl- guanine-alkyltransferase (AGAT), an enzyme involved in the mismatch repair system. T and P are active against malignant gliomas while thalidomide (TH) is emerging as an inhibitor of angiogenesis. Patients and Methods: Triplets of patients with malignant brain tumors received escalating doses of P, T and TH up to the dose-limiting-toxicity (DLT) and the maximal tolerated dose (MTD). Results: Seventeen patients were enrolled and a total of 74 cycles were delivered. The MTD was P 75 mg/m² day 1 and T 150 mg/m² days 1 to 5 every 21 days with a concomitant 200 mg total daily dose of TH. DLT events were G4 thrombocytopenia and febrile neutropenia. Conclusion: Concomitant administration of P 75 mg/m² day 1, T 150 mg/m² days 1 to 5 every 21 days and concomitant TH at a total daily dose of 150 mg is feasible and safe. Early efficacy data are encouraging and a phase II study is ongoing.

Original language	English
Pages (from-to)	1019-1024
Number of pages	6
Journal	Anticancer Research
Volume	27
Issue number	2
Publication status	Published - Mar 2007

Keywords

Brain
Chemotherapy
Cisplatin
Gliomas
Malignant
Temozolomide
Thalidomide
Tumors

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors'. Together they form a unique fingerprint.

Cite this

A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors. / Zustovich, Fable; Cartei, Giuseppe; Ceravolo, Renato; Zovato, Stefania; Della Puppa, Alessandro; Pastorelli, Davide; Mattiazzi, Martina; Bertorelle, Roberta; Gardiman, Marina Paola.

In: Anticancer Research, Vol. 27, No. 2, 03.2007, p. 1019-1024.

Research output: Contribution to journal › Article › peer-review

@article{7e74b757d5ea41e086d876261e641339,

title = "A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors",

abstract = "Background: There is pre-clinical evidence of synergism between cisplatin (P) and temozolomide (T) due to higher inhibition by T of O6-alkyl- guanine-alkyltransferase (AGAT), an enzyme involved in the mismatch repair system. T and P are active against malignant gliomas while thalidomide (TH) is emerging as an inhibitor of angiogenesis. Patients and Methods: Triplets of patients with malignant brain tumors received escalating doses of P, T and TH up to the dose-limiting-toxicity (DLT) and the maximal tolerated dose (MTD). Results: Seventeen patients were enrolled and a total of 74 cycles were delivered. The MTD was P 75 mg/m2 day 1 and T 150 mg/m2 days 1 to 5 every 21 days with a concomitant 200 mg total daily dose of TH. DLT events were G4 thrombocytopenia and febrile neutropenia. Conclusion: Concomitant administration of P 75 mg/m2 day 1, T 150 mg/m2 days 1 to 5 every 21 days and concomitant TH at a total daily dose of 150 mg is feasible and safe. Early efficacy data are encouraging and a phase II study is ongoing.",

keywords = "Brain, Chemotherapy, Cisplatin, Gliomas, Malignant, Temozolomide, Thalidomide, Tumors",

author = "Fable Zustovich and Giuseppe Cartei and Renato Ceravolo and Stefania Zovato and {Della Puppa}, Alessandro and Davide Pastorelli and Martina Mattiazzi and Roberta Bertorelle and Gardiman, {Marina Paola}",

year = "2007",

month = mar,

language = "English",

volume = "27",

pages = "1019--1024",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2",

}

TY - JOUR

T1 - A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors

AU - Zustovich, Fable

AU - Cartei, Giuseppe

AU - Ceravolo, Renato

AU - Zovato, Stefania

AU - Della Puppa, Alessandro

AU - Pastorelli, Davide

AU - Mattiazzi, Martina

AU - Bertorelle, Roberta

AU - Gardiman, Marina Paola

PY - 2007/3

Y1 - 2007/3

N2 - Background: There is pre-clinical evidence of synergism between cisplatin (P) and temozolomide (T) due to higher inhibition by T of O6-alkyl- guanine-alkyltransferase (AGAT), an enzyme involved in the mismatch repair system. T and P are active against malignant gliomas while thalidomide (TH) is emerging as an inhibitor of angiogenesis. Patients and Methods: Triplets of patients with malignant brain tumors received escalating doses of P, T and TH up to the dose-limiting-toxicity (DLT) and the maximal tolerated dose (MTD). Results: Seventeen patients were enrolled and a total of 74 cycles were delivered. The MTD was P 75 mg/m2 day 1 and T 150 mg/m2 days 1 to 5 every 21 days with a concomitant 200 mg total daily dose of TH. DLT events were G4 thrombocytopenia and febrile neutropenia. Conclusion: Concomitant administration of P 75 mg/m2 day 1, T 150 mg/m2 days 1 to 5 every 21 days and concomitant TH at a total daily dose of 150 mg is feasible and safe. Early efficacy data are encouraging and a phase II study is ongoing.

AB - Background: There is pre-clinical evidence of synergism between cisplatin (P) and temozolomide (T) due to higher inhibition by T of O6-alkyl- guanine-alkyltransferase (AGAT), an enzyme involved in the mismatch repair system. T and P are active against malignant gliomas while thalidomide (TH) is emerging as an inhibitor of angiogenesis. Patients and Methods: Triplets of patients with malignant brain tumors received escalating doses of P, T and TH up to the dose-limiting-toxicity (DLT) and the maximal tolerated dose (MTD). Results: Seventeen patients were enrolled and a total of 74 cycles were delivered. The MTD was P 75 mg/m2 day 1 and T 150 mg/m2 days 1 to 5 every 21 days with a concomitant 200 mg total daily dose of TH. DLT events were G4 thrombocytopenia and febrile neutropenia. Conclusion: Concomitant administration of P 75 mg/m2 day 1, T 150 mg/m2 days 1 to 5 every 21 days and concomitant TH at a total daily dose of 150 mg is feasible and safe. Early efficacy data are encouraging and a phase II study is ongoing.

KW - Brain

KW - Chemotherapy

KW - Cisplatin

KW - Gliomas

KW - Malignant

KW - Temozolomide

KW - Thalidomide

KW - Tumors

UR - http://www.scopus.com/inward/record.url?scp=34247166361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247166361&partnerID=8YFLogxK

M3 - Article

C2 - 17465237

AN - SCOPUS:34247166361

VL - 27

SP - 1019

EP - 1024

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -

A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this